Understand the source comparison
Best Peptides for Male Pattern Baldness: Detailed Comparison
Before applying any peptide protocol, understand the mechanism it targets and the stage of miniaturisation where it's most effective. Early-stage androgenetic alopecia (Norwood I–III) responds better to stem cell activators; advanced cases (Norwood IV–VI) requ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before applying any peptide protocol, understand the mechanism it targets and the stage of miniaturisation where it's most effective. Early-stage androgenetic alopecia (Norwood I–III) responds better to stem cell activators; advanced cases (Norwood IV–VI) require extracellular matrix rebuilders combined with anagen extenders.
- GHK-Cu (Copper Peptide)
- Rebuilds collagen IV and laminin-5 in basement membrane; stimulates TIMP expression to prevent matrix degradation
- 22% increase in follicle diameter (Journal of Cosmetic Dermatology, 2024); 28.6% terminal hair density increase when combined with microneedling (Dermatologic Surgery, 2022)
- Topical 2–5% solution applied twice weekly post-microneedling (1.0mm depth); store reconstituted solution at 2–8°C, use within 21 days
- Best for mid-stage miniaturisation (Norwood III–IV) where basement membrane integrity is compromised but follicles remain viable
- TB-500 (Thymosin Beta-4)
- Activates follicle stem cells in bulge region; upregulates VEGF and actin polymerisation to initiate anagen re-entry
- 35–42% follicle density increase in preclinical models; Phase II human trials ongoing as of 2026
- Subcutaneous injection 2–5mg weekly for 8–12 weeks; refrigerate lyophilised powder at −20°C before reconstitution
- Most effective in early-stage cases (Norwood I–III) where stem cell pools are depleted but not exhausted; less effective once fibrosis develops
- Cartalax
- Inhibits TGF-beta signalling to extend anagen phase; modulates growth factor receptor expression
- 18–24% anagen phase extension in follicle culture studies; human efficacy data limited to observational reports
- Topical or subcutaneous; typical protocol 10mg administered 2–3 times weekly for 12 weeks
- Useful as adjunct to DHT blockers in patients experiencing persistent shedding despite androgen suppression
- GHK (Non-Copper Form)
- Antioxidant and anti-inflammatory without matrix rebuilding
- Minimal hair growth evidence; primarily studied for wound healing
- Generally not recommended as monotherapy for androgenetic alopecia
- Copper complexation is required for follicle efficacy. Non-copper GHK lacks the mechanism